Stock OTLK OUTLOOK THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Revisions Outlook Therapeutics, Inc.

Equities

OTLK

US69012T3059

Market Closed - Nasdaq
Other stock markets
 03:59:45 2024-06-04 pm EDT 		5-day change 1st Jan Change
7.2 USD +2.86% Intraday chart for Outlook Therapeutics, Inc. -9.26% -8.63%
May. 28 Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD MT
May. 28 Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD CI

Turnover - Change in analysts' estimates

Earnings Per Share (EPS) - Change in analysts' estimates

EBIT - Change in analysts' estimates

Turnover

Earnings Per Share (EPS)

EBIT

  1. Stock Market
  2. Equities
  3. OTLK Stock
  4. Revisions Outlook Therapeutics, Inc.